Fisher Scientific International Inc
Fisher Scientific International — Investor Presentation (February 2005)
27 slides from Fisher Scientific International's investor presentation, Feb 10, 2005

Slide 1: Safe Harbor and Regulation G Statement
Safe Harbor and Regulation G Statement The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This presentation contains these types of statements

Slide 2: Key Facts
Key Facts • Founded: 1902 • Revenue (2005F): $5.6 billion • Customers: 350,000 • Products: 600,000 SKUs 60% proprietary 80% consumable • Equity market cap: $8.0 billion* • Index: S&P 500 • Earnings per share (2005F) $3.45 — $3.60 27%* Return to Shareholders since 1991 IPO * As of February 8, 2005.

Slide 3: Investment Highlights
Investment Highlights World Leader in Growing Markets World Leader in Growing Markets World Leader in Growing Markets World Leader in Growing Markets World Leader in Growing Markets Strong earnings and cash flow growth

Slide 4: World Leader in Growing Markets
World Leader in Growing Markets Markets Served Global Market: $50 billion Long Term Growth Rate: 5 — 8%

Slide 5: World Leader in Growing Markets
World Leader in Growing Markets Market Drivers Markets Served lGrowth in R&D spending lIncreased focus on proteomics lPressure on drug development costs l Global Market: $23 billion* Long Term Growth Rate: 5 — 8% *Sources: Frost & Sullivan, Lab Products Association, and Fisher management estimates.

Slide 6: World Leader in Growing Markets
World Leader in Growing Markets Market Drivers Markets Served —— — lGrowing number of biotech drugs lConcern about contamination Global Market: $5 billion* Long Term Growth Rate: 15 — 25% *Includes: bioreactors, containers, serum and media, process liquids, chromatography and filtration products and

Slide 7: World Leader in Growing Markets
World Leader in Growing Markets Market Drivers Markets Served lAging population lProliferation of patient testing lIncreased focus on specialized tests U.S. Market: $10 billion* Long Term Growth Rate: 4 — 5% *Sources: Freedonia Group and Fisher management estimates.

Slide 8: World Leader in Growing Markets
World Leader in Growing Markets Market Drivers Markets Served lExpansion of environmental and safety regulations lGrowth in homeland security spending lIncreased focus on bioterrorism protection U.S. Market: $12 billion* Long Term Growth Rate: 4 — 6% *Sources: Frost & Sullivan, RK Miller, and Fisher

Slide 9: Revenues by Market and by Customer
Fisher Scientific — Revenues by Market Revenues by Customer Scientific Products & Services 77% HealthCare Products & Services 23%

Slide 10: Premier Global Brand
Premier Global Brand lBroad portfolio of products lExtensive suite of services lGlobally-integrated supply-chain lPowerful sales and marketing network l Enhanced by acquisition strategy

Slide 11: Premier Global Brand: Broad portfolio of products
Premier Global Brand Broad portfolio of products Unmatched Product Offering

Slide 12: Premier Global Brand: Extensive suite of services
Premier Global Brand Extensive suite of services ·Pharmaceutical Services - -Clinical trials support - -Custom chemical synthesis - -IVD contract manufacturing ·Supply-Chain Management Services - -Cost-optimization programs - -Lab start-up programs - -On-site maintenance of equipment Value-added ser

Slide 13: Premier Global Brand: Globally-integrated supply-chain
Premier Global Brand Globally-integrated supply-chain lTechnology-based supply-chain management lGlobal sourcing capabilities lLeading e-commerce capabilities - - Efficient supply-chain solutions

Slide 14: Premier Global Brand: Powerful sales and marketing network
Premier Global Brand Powerful sales and marketing network l2,700 sales representatives l800 technical specialists - -Life Science - -Chemical - -Diagnostic - -Instrumentation Enabling Discovery

Slide 15: Premier Global Brand: Enhanced by acquisition strategy
Premier Global Brand Enhanced by acquisition strategy ·Completed 37 acquisitions since 1991 - -Extended geographic reach - -Expanded into related markets - -Enhanced portfolio of proprietary products and services Strong acquisition track record

Slide 16: Opportunities for Profitable Growth
Opportunities for Profitable Growth Increase Margins and Cash Flow ·Execute Apogent integration plan ·•Maximize operating efficiencies ·•Reduce working capital Enhance Revenue Growth ·New product development ·•Expand pharma services ·•Leverage sales and marketing footprint

Slide 17: Opportunities for Profitable Growth: Increase margins and cash flow
Opportunities for Profitable Growth Increase margins and cash flow ·Execute Apogent integration plan ·Maximize operating efficiencies ·Reduce working capital ·Achieve $100 million of synergies ·•Leverage fixed cost structure ·Execute working capital initiatives

Slide 18: Opportunities for Profitable Growth: Increase revenue growth
Opportunities for Profitable Growth Increase revenue growth ·New product development ·Expand pharma services ·Leverage sales and marketing footprint ·Serum free media ·Disposable bioprocess containers ·•Analytical product testing ·Ancillary distribution services ·Cross-selling opportunities ·Technic

Slide 19: Powerful Channel Position
Powerful Channel Position Serving 350,000 customers in 145 countries

Slide 20: Full Year 2004 Results
Full Year 2004 Results Full Year 2004 Growth — Revenue: $4.7 Billion +31% Operating margin: 10.2% +240 bps Earnings per share: $2.89 +22% Free cash flow per share*: $3.25 +43% Excludes restructuring and non-recurring expenses *Defined as cash provided by operating activities less capital expenditure

Slide 21: Sales Growth
Sales Growth ($ in Billions) * Midpoint of guidance previously issued by Fisher Scientific on Feb. 8, 2005, which reflects revenue growth of 20.0 percent to 22.0 percent for 2005. Guidance excludes the impact of foreign exchange.

Slide 22: Earnings Per Share Growth
Earnings Per Share Growth * Range of guidance previously issued by Fisher Scientific on Feb. 8, 2005. Excludes goodwill amortization, restructuring and nonrecurring expenses. ** Midpoint of guidance range of 13.3 percent to 13.5 percent as previously issued by Fisher Scientific on Feb. 8, 2005. Excl

Slide 23: Strong Free Cash Flow Generation
Strong Free Cash Flow Generation * Midpoint of guidance range of $385 — $415 million as previously issued by Fisher Scientific on Feb. 8, 2005. ** Defined as cash provided by operating activities less capital expenditures divided by diluted shares outstanding.

Slide 24: Investment Highlights
Investment Highlights lWorld leader in growing marketslPremier global brand lOpportunities for profitable growth lProven track record Strong earnings and cash flow growth

Slide 25: Fisher Scientific International Inc. The World Leader in Serving Science
[F LOGO] Fisher Scientific International Inc. The World Leader in Serving Science

Slide 26: Fisher Scientific International Inc.
Fisher Scientific International Inc. The World Leader in Serving Science

Slide 27: Supplementary Financial Information
Supplementary Financial Information (in millions, except per share amounts) Fisher Scientific International Inc. Statement of Operations (in millions, except per share data) Twelve Months Ended Twelve Months Ended Twelve Months Ended #REF! #REF! #REF! —— —— — 2002 2002 2002 2001 2001 2001 2001 Sales
Source: SEC EDGAR · 8-K filed Feb 10, 2005
More decks from Fisher Scientific International Inc
Merger or Acquisition (May 2006)23 slides · May 8, 2006
Lehman Brothers Ninth Annual Global Healthcare Conference 200619 slides · Mar 8, 2006
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 200612 slides · Feb 9, 2006
Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 200511 slides · Jun 15, 2005
Banc of America Securities Health Care Conference 200511 slides · May 17, 2005
Baird Growth Stock Conference 200526 slides · May 12, 2005